A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Tango Therapeutics, Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
PharmaMar
Instituto do Cancer do Estado de São Paulo
NGM Biopharmaceuticals, Inc
Shenzhen BinDeBio Ltd.